X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES IPCA LABS ALKEM LABORATORIES/
IPCA LABS
 
P/E (TTM) x - 42.1 - View Chart
P/BV x 7.4 3.2 229.5% View Chart
Dividend Yield % 0.6 0.2 367.5%  

Financials

 ALKEM LABORATORIES   IPCA LABS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
IPCA LABS
Mar-17
ALKEM LABORATORIES/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,589643 247.1%   
Low Rs1,232503 245.0%   
Sales per share (Unadj.) Rs417.5254.4 164.1%  
Earnings per share (Unadj.) Rs56.316.1 350.3%  
Cash flow per share (Unadj.) Rs64.729.8 217.3%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.2 515.8%  
Book value per share (Unadj.) Rs292.9194.6 150.6%  
Shares outstanding (eoy) m119.57126.20 94.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.3 150.0%   
Avg P/E ratio x25.135.7 70.3%  
P/CF ratio (eoy) x21.819.2 113.3%  
Price / Book Value ratio x4.82.9 163.5%  
Dividend payout %22.66.2 362.5%   
Avg Mkt Cap Rs m168,65372,300 233.3%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m9,1716,960 131.8%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m49,91532,106 155.5%  
Other income Rs m1,645226 728.9%   
Total revenues Rs m51,56132,332 159.5%   
Gross profit Rs m8,4824,448 190.7%  
Depreciation Rs m1,0061,730 58.2%   
Interest Rs m671241 278.5%   
Profit before tax Rs m8,4512,703 312.6%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606675 237.9%   
Profit after tax Rs m6,7312,028 331.9%  
Gross profit margin %17.013.9 122.7%  
Effective tax rate %19.025.0 76.1%   
Net profit margin %13.56.3 213.5%  
BALANCE SHEET DATA
Current assets Rs m27,06217,340 156.1%   
Current liabilities Rs m15,3249,559 160.3%   
Net working cap to sales %23.524.2 97.0%  
Current ratio x1.81.8 97.4%  
Inventory Days Days67100 66.3%  
Debtors Days Days4157 72.6%  
Net fixed assets Rs m12,61020,779 60.7%   
Share capital Rs m239252 94.7%   
"Free" reserves Rs m34,49024,499 140.8%   
Net worth Rs m35,02724,553 142.7%   
Long term debt Rs m1,2123,517 34.4%   
Total assets Rs m54,38739,595 137.4%  
Interest coverage x13.612.2 111.3%   
Debt to equity ratio x00.1 24.1%  
Sales to assets ratio x0.90.8 113.2%   
Return on assets %13.65.7 237.5%  
Return on equity %19.28.3 232.7%  
Return on capital %24.910.5 237.0%  
Exports to sales %12.948.6 26.6%   
Imports to sales %3.114.2 21.7%   
Exports (fob) Rs m6,46115,617 41.4%   
Imports (cif) Rs m1,5404,571 33.7%   
Fx inflow Rs m6,56315,617 42.0%   
Fx outflow Rs m3,0125,828 51.7%   
Net fx Rs m3,5529,790 36.3%   
CASH FLOW
From Operations Rs m7,2592,764 262.6%  
From Investments Rs m1,864-1,432 -130.2%  
From Financial Activity Rs m-9,273-1,591 582.7%  
Net Cashflow Rs m-150-259 58.0%  

Share Holding

Indian Promoters % 66.9 45.9 145.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 11.4 290.4%  
FIIs % 0.0 25.3 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 17.4 -  
Shareholders   68,381 36,892 185.4%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  STRIDES SHASUN LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS